Studies indicate that puerarin treatment in tMCAO rats decreases cerebral infarction volume, enhances neural function, and lowers pro‐inflammatory factors IL‐1β, IL‐6, and TNF‐α, likely via CAP activation [36]. This evidence concerns the gene IL6 and brain infarction.